Insider

Sabtu, 25 Juli 2009
Jam 09:02

OREX: Insider tinggi dan saham ini Up-Trend. Insider beli di $7.5

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. The combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Contrave is a fixed dose combination of naltrexone SR and bupropion SR. Empatic is a fixed dose combination of zonisamide SR and bupropion SR.

Perusahaan ini buat Obat untuk kurangai Berat Badan dgn nama 'Contrave' dan sekarang sdh Phase III, jika lolos dari FDA (Food Drug Administration) maka boleh di jual ke pasar.

Kita tidak tahu kapan Phase III akan diumumkan, tapi Insider sdh beli banyak
Mereka pasti tahu sesuatu yang kita tidak tahu. Ikut aja!


Peter